Last reviewed · How we verify
NCT06931184: FALCON
Self- Sampling in Cervical Cancer Routine Screening
NA trial testing self-sampling in Cervical Cancer Screening in 40,000 participants. Enrolling by invitation.
31 December 2025
Quick facts
| Lead sponsor | Tampere University Hospital |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 40,000 |
| Start date | 11 June 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- self-sampling
Conditions studied
- Cervical Cancer Screening — all drugs for Cervical Cancer Screening →
Sponsor
Tampere University Hospital
Who can join
Adults 30 to 65, female only, with Cervical Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SELF-SAMPLING IN CERVICAL CANCER ROUTINE SCREENING (FALCON) -Study implements a self-sampling option for the non-attendees of the national cervical cancer screening program in the Wellbeing Services County of Pirkanmaa. HPV primary testing is currently preferred method for cervical cancer screening. The HPV-DNA self-sampling has been shown to have screening performance equal to that of provider-obtained samples. In 2024, those turning 30, 35, 40, 45, 50, 55, 60, or 65 had the opportunity to participate in the FALCON study if they do not respond to the first invitation to cervical cancer screening. From March 2025 also women living in Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia can take part to the study. The main objective of the FALCON study is to increase the current coverage of the cervical cancer screening program in the Pirkanmaa, Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia region and assess how acceptable self-sampling is for women.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Introducing self-sampling for cervical cancer screening: A regional implementation study in Pirkanmaa, Finland.
Kyllönen S, Saloranta S, Kares S, Mustila A, et al · · 2026 · PMID 42244134 · DOI 10.1111/aogs.70273
Verify or expand the search:
- PubMed search for NCT06931184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer Screening
Currently open trials in the same condition.
- NCT06968871 — Ameliorated Pap Tests and Cervical Cancer Screening Participation · NA · recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT07171658 — Breast Cancer-Related Approach for Increasing Cervical Cancer Screening · NA · recruiting
- NCT07581873 — Education and Health in Women With Cervical Cancer · NA · active not recruiting
- NCT07181278 — Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of De · NA · recruiting
Other Tampere University Hospital trials
Trials by the same sponsor.
- NCT07315568 — Couples and Microbial Diversity · not yet recruiting
- NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
- NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
- NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
- NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06931184 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06931184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing